Adaptimmune is a leader in TCR T-cell therapy, focused on developing novel cancer immunotherapy products. We utilize the bodyâs own machinery â the T-cell â to target and destroy cancer cells by increasing the affinity of naturally occurring T-cell receptors (TCRs). We have developed a proprietary T-cell receptor platform that enables us to identify cancer targets, find and genetically engineer T-cell receptors, or TCRs, and produce TCR therapeutic candidates called SPEAR (Specific Peptide Enhanced Affinity Receptor) T-cells that recognize these targets on cancer cells. We engineer a patientâs own T-cells to express our SPEAR TCRs to target and potentially destroy tumors. Source
No articles found.
CPSI is a leading provider of healthcare solutions and services for community hosp...
CPSI is a leading provider of healthcare soluti...
Ligand is a biopharmaceutical company focused on developing or acquiring technolog...
Ligand is a biopharmaceutical company focused o...
T2 Biosystems, a leader in the development and commercialization of innovative med...
T2 Biosystems, a leader in the development and ...
KemPharmÂŽ is a clinical-stage specialty pharmaceutical company engaged in the dis...
KemPharmÂŽ is a clinical-stage specialty pharma...
CNS Pharmaceuticals is a pre-clinical stage biotechnology company specializing in ...
CNS Pharmaceuticals is a pre-clinical stage bio...
Seres Therapeutics, Inc. is a microbiome therapeutics platform company developing ...
Seres Therapeutics, Inc. is a microbiome therap...
We are a leading precision oncology company focused on helping conquer cancer glob...
We are a leading precision oncology company foc...
Join the National Investor Network and get the latest information with your interests in mind.